214 related articles for article (PubMed ID: 8055814)
41. A case of acromegaly associated with Graves' disease. A possible role of endogenous TRH and an effect of bromocriptine on GH and TSH secretion.
Demura R; Demura H; Odagiri E; Shizume K
Endocrinol Jpn; 1984 Dec; 31(6):801-7. PubMed ID: 6442699
[TBL] [Abstract][Full Text] [Related]
42. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly.
de Herder WW; Uitterlinden P; van der Lely AJ; Hofland LJ; Lamberts SW
Eur J Endocrinol; 1995 Aug; 133(2):195-9. PubMed ID: 7544670
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of GH paradoxical responses to TRH and LHRH in acromegalic patients during long-term treatment with octreotide.
Merola B; Colao A; Cataldi M; Rossi E; Selleri A; Briganti F; Schettini G; Bellastella A; Lombardi G
Horm Res; 1992; 37(1-2):18-22. PubMed ID: 1398471
[TBL] [Abstract][Full Text] [Related]
44. Long-term treatment of acromegaly with octreotide (Sandostatin).
Page MD; Millward ME; Hourihan M; Hall R; Scanlon NF
Horm Res; 1990; 33 Suppl 1():20-30; discussion 30-1. PubMed ID: 2192978
[TBL] [Abstract][Full Text] [Related]
45. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly.
Fløgstad AK; Halse J; Grass P; Abisch E; Djøseland O; Kutz K; Bodd E; Jervell J
J Clin Endocrinol Metab; 1994 Aug; 79(2):461-5. PubMed ID: 8045964
[TBL] [Abstract][Full Text] [Related]
46. TRH-Gly, a precursor of TRH, alters GH secretion in acromegaly.
Mori M; Satoh T; Miyashita K; Yamada M; Murakami M; Iriuchijima T; Ohshima K; Kobayashi I; Kobayashi S
Life Sci; 1991; 49(14):1031-7. PubMed ID: 1909766
[TBL] [Abstract][Full Text] [Related]
47. Secretion of glycoprotein hormone alpha-subunit by pituitary tumors.
Ishibashi M; Yamaji T; Takaku F; Teramoto A; Fukushima T
J Clin Endocrinol Metab; 1987 Jun; 64(6):1187-93. PubMed ID: 2437140
[TBL] [Abstract][Full Text] [Related]
48. Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients.
De Marinis L; Mancini A; Zuppi P; Fiumara C; Conte G; Sammartano L; Fabrizi ML; Valle D
Exp Clin Endocrinol Diabetes; 1996; 104(1):67-71. PubMed ID: 8750573
[TBL] [Abstract][Full Text] [Related]
49. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
50. Lack of effect of thyroid hormones on the growth hormone response to thyrotropin-releasing hormone in acromegaly.
Carlson HE; Sowers JR; Rand RW
Metabolism; 1977 Jul; 26(7):801-5. PubMed ID: 405552
[TBL] [Abstract][Full Text] [Related]
51. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
Chang CC; Chen FW; Hsieh HC
Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
[TBL] [Abstract][Full Text] [Related]
52. Growth hormone response to thyrotropin-releasing hormone in acromegalic patients: reproducibility and dose-response study.
Villabona CM; Soler J; Virgili N; Gómez JM; Montaña E; Navarro MA
Horm Res; 1992; 37(1-2):14-17. PubMed ID: 1398470
[TBL] [Abstract][Full Text] [Related]
53. Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects.
Camanni F; Massara F; Belforte L; Rosatello A; Molinatti GM
J Clin Endocrinol Metab; 1977 Mar; 44(3):465-73. PubMed ID: 838847
[TBL] [Abstract][Full Text] [Related]
54. Experiences with bromocriptine treatment in acromegaly--a preliminary report.
Nilsson A
Acta Endocrinol Suppl (Copenh); 1978; 216():217-24. PubMed ID: 274038
[TBL] [Abstract][Full Text] [Related]
55. Heterogeneous responses to the long-term treatment of active acromegaly with octreotide.
Chang CL; Kuo HF; Fang VS; Hwu CM; Lai TY; Yang HJ; Kwok CF; Ho LT
Endocr J; 1996 Aug; 43(4):447-56. PubMed ID: 8930535
[TBL] [Abstract][Full Text] [Related]
56. Octreotide treatment of acromegaly.
Wass JA
Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
[TBL] [Abstract][Full Text] [Related]
57. Prolactin response to thyrotropin-releasing hormone in normoprolactinemic patients with ovulatory dysfunction and its use for selection of candidates for bromocriptine therapy.
Steinberger E; Nader S; Rodriguez-Rigau L; Ayala C; Smith K
J Endocrinol Invest; 1990 Sep; 13(8):637-42. PubMed ID: 2148756
[TBL] [Abstract][Full Text] [Related]
58. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
Candrina R
Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
[TBL] [Abstract][Full Text] [Related]
59. Abnormal growth hormone responses to CB-154 and thyrotropin-releasing hormone (TRH) in patients with acromegaly.
Hanew K; Aida M; Sasaki A; Mouri T; Yoshinaga K
Tohoku J Exp Med; 1979 Jan; 127(1):53-62. PubMed ID: 104407
[TBL] [Abstract][Full Text] [Related]
60. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide.
Li JK; Chow CC; Yeung VT; Mak TW; Ko GT; Swaminathan R; Chan JC; Cockram CS
Aust N Z J Med; 2000 Aug; 30(4):457-61. PubMed ID: 10985510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
